STOCK TITAN
  1. Home
  2. MVIR

MVIR Stock Price, News & Analysis

MVIR
Published by Stock Titan Data refreshed

What Changed

Company Description

This page collects what Stock Titan holds for MVIR, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

Latest News

View All
—

Medivir to present at the Pareto Securities Healthcare Conference

conferences
—

Medivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMO

—

Medivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16

conferences clinical trial
—

Medivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in September

conferences clinical trial
—

Number of shares and votes in Medivir AB on 28 June 2024

—

Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI

—

Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility

clinical trial
—

Medivir to present at Redeye Growth Day

conferences
—

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

—

Medivir brings the Q1 webcast forward to 10 a.m. on April 30

MVIR has 10 recent news articles. Key topics include conferences, clinical trial. View all MVIR news →

SEC Filings

View All

No SEC filings available for MVIR.